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Marketing the Research Missions of Academic Medical Centers: Why 
Messages Blurring Lines Between Clinical Care and Research Are Bad for both
Business and Ethics
Mark Yarborough, Timothy Houk, Sarah Tinker Perrault, Yael Schenker, and 
Richard R. Sharp
Abstract: Academic Medical Centers (AMCs) offer patient care and perform 
research. Increasingly, AMCs advertise to the public in order to garner 
income that can support these dual missions. In what follows, we raise 
concerns about the ways that advertising blurs important distinctions 
between them. Such blurring is detrimental to AMC efforts to fulfill critically 
important ethical responsibilities pertaining both to science communication 
and clinical research, because marketing campaigns can employ hype that 
weakens research integrity and contributes to therapeutic misconception 
and misestimation, undermining the informed consent process that is 
essential to the ethical conduct of research. We offer ethical analysis of 
common advertising practices that justify these concerns. We also suggest 
the need for a deliberative body convened by the Association of American 
Medical Colleges and others to develop a set of voluntary guidelines that 
AMCs can use to avoid in the future, the problems found in many current 
AMC advertising practices. 
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The intertwined missions of patient care, health professions education, 
and research,1 all of which seek to improve the well-being of communities, 
establish Academic Medical Centers (AMCs) as a central component of our 
nation’s health care system. The interdependent commitments to both 
education and research in pursuit of quality health care is what makes them 
“academic,” and thus distinctive in our health care system, underscoring the 
need for AMC leaders to continually seek ways to grow their learning and 
discovery efforts. Doing so in ethical ways has become increasingly difficult 
in light of the health care system’s ever-growing reliance on market forces. 
Whether competing for the business of individual patients or the health plans
that insure them, AMCs must appeal to consumers and their health care 
needs and expectations, in efforts to sustain and grow market shares. In this 
environment, AMCs, like other health systems, have increasingly turned to 
marketing.  
The Challenges of Responsible Advertising in a Competitive 
Environment
Herein lies a substantial challenge. AMCs must compete against rivals 
who do not share the burdens of extensive education and research missions 
(the presence of medical students in the examination room, care delivered 
by a resident physician, or a faculty expected to conduct clinical research), 
none of which are necessarily seen as advantageous by health care or 
insurance consumers. Even with these challenges, AMCs must appeal, as 
their competitors do, to the health care sensibilities of individual consumers. 
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AMCs commonly do so by claiming an institution's research places it at the 
forefront of efforts to improve healthcare. This invites potential patients to 
infer not just that an AMC’s practitioners have superior clinical skills but that 
the AMC offers more effective tools for treating disease, even when such an 
inference may not be warranted.
For example, imagine you are reading an article online and click a 
short video ad for your local AMC. It shows an apparently healthy person 
doing an everyday activity. The voiceover explains that this activity was 
previously impossible for the person shown, but that thanks to a medical 
intervention provided in a clinical trial—described as “the first of its kind,” 
“innovative,” or “pioneering”—the person’s abilities and quality of life have 
been restored. The ad is heavily branded with the identity of the AMC; it 
includes the patient saying how that AMC gave her back her life, or gave him
the gift of more time with loved ones. The implication is clear: cutting-edge 
research at the AMC is restoring lost abilities and saving lives. This example 
is a composite of actual elements frequently used in AMC marketing 
campaigns, and many readers of this journal will recall similar ads from their 
own institutions. 
It is not surprising that we encounter such AMC ads; given the 
commercial benefits that can accrue from them,4 ads are commonly 
designed for broad appeal. According to a study of print advertisements, 
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AMC ads often (53.3%) promote specific clinical units like cancer centers that
can have high volumes of clinical trials.5 A New York Times article describes 
various tactics that multiple cancer centers have, like other units, used in 
their campaigns:6 tout “innovation,” champion their “pioneering” physicians, 
highlight patient testimonials, and rely on single anecdotes rather than 
clinical data to persuade people of the merits of a given center. 
These kinds of ads are troubling on two fronts. First, due to their lack of
balanced information about research, they are an instance of irresponsible 
science communication and thus undermine research integrity.7 Second, 
they go against the Association of American Medical Colleges’ (AAMC) own 
standards about the ethical conduct of research. These standards are 
reflected in a public assurance about ethics and research made by the AAMC
in 2000 when the nation’s medical schools were among more than 300 
academic, scientific, and patient health organizations that issued “Clinical 
Research: A Reaffirmation of Trust Between Medical Science and the Public.”8
This “reaffirmation of trust” followed widely publicized research ethics lapses
in the late 1990s, and was issued to show the public the signatories’ 
commitment to conducting research responsibly. Among other things, the 
signatories affirmed that research volunteers “have a right to expect that 
they be treated with beneficence, justice, and respect.” Most relevant to our 
purposes, however, was that signatories also pledged themselves to 
ensuring that “patients understand that research procedures are not 
necessarily treatment and, in given instances, may not benefit themselves in
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any way and may possibly harm them,” an implicit recognition of the 
important ethical dimensions of science communication implicated in the 
informed consent process for clinical research. 
To explore these concerns about AMC marketing practices, we 
highlight major ethical issues in science communication and research ethics 
that are frequently implicated in marketing campaigns, explain why more 
careful review of them is required if AMCs are to honor critical ethical 
standards while communicating about and conducting their clinical research,
and suggest a way that AMCs can better fulfill the promises they made in the
2000 reaffirmation of trust. 
Why We Need to Recognize that Ads Can Influence Informed 
Consent
Our ethical concerns originate in the fact that ads touting research can
have a detrimental spillover effect on individuals who may later be recruited 
into clinical trials. The major aim of such ads is to steer people to an AMC, 
rather than another hospital, by suggesting that the AMC offers distinctive 
care because of its research mission. Granted, care can be distinctive in any 
number of ways. For example, it can be distinctive because all standard care 
services are available under one roof or because the hospital offers a broad 
range of ancillary services, such as nutritional or psychological counseling, in
addition to standard care. However, these characteristics are not unique to 
AMCs. What is most likely to be distinctive about AMC units that conduct 
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clinical trials (e.g., cancer centers) is access to clinical trials frequently not 
available at other centers in the same geographic area. Thus, advertising an 
AMC as offering special health benefits encourages the obvious inference 
that clinical trials conducted there confer these on patients. 
One upshot of such advertising, if it actually steers someone to an AMC
who otherwise would receive care elsewhere, is that they end up at a clinical 
unit that is conducting research in which they may be asked to participate. 
When this occurs, prospective research participants have seen ads that blur 
the lines between proven medical care and clinical investigations. This 
potentially undermines the informed consent process which, we are 
reminded by the Nuremberg Code, is “absolutely essential” to the ethical 
conduct of research and whose centrality to ethical research the 
“reaffirmation of trust” signatories celebrated in 2000. 
How Ads Can Impact the Informed Consent Process
To understand how ads can blur lines between medical care and 
research, and why this blurring threatens informed consent, it helps to think 
about advertising in light of the health literacy context in which advertising 
occurs, as well as in light of existing problems with informed consent. Most 
people fail to understand health care information: the first National 
Assessment of Adult Literacy found that only 12% of the US population was 
“proficient” in health language.9 Only 53% had “intermediate” literacy, while 
35% were rated as “Basic” or “Below Basic.” Thus, people who are “non-
7
proficient” with health language are likely in the majority of those reached 
by ads that steer people toward clinical settings where research is routinely 
conducted. Furthermore, even the minority of “proficient” people live in a 
culture permeated by an understanding of medicine based on a narrative of 
progress and continual improvement. Thus, they will favorably interpret 
terms like “pioneering” or “innovative,” when attached to “care” or 
“physician.” Otherwise such terms would not be so prominent in campaigns, 
nor would campaigns cast past research advances as dispositive of future 
ones in order to influence current patients. 
One might contend that the informed consent process will protect 
people from any worrisome misunderstandings stemming from ads. One 
could assume such broad protection across the population, however, only by 
ignoring the fact that informed consent is an ill-suited decisionmaking model 
for the many candidates for clinical trials who prefer guidance from 
professionals in their decisionmaking.10 By their nature, such individuals want
to be influenced by others and thus may feel reassured by the kinds of 
marketing efforts that concern us. So, we ought not underestimate how 
many people can be swayed by AMC advertisements. 
Some might still object that AMC advertising cannot threaten informed 
consent, even for patients who seek strong guidance, because it occurs so 
early in the decisionmaking process. Patients who see AMC ads and 
ultimately consent to some clinical trial will have plenty of relevant 
information presented to them between seeing the ad and consenting to any
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particular trial. We think this objection is contrary to the Food and Drug 
Administration’s (FDA) view that first impressions regarding research can 
affect subsequent deliberation about it. That is why the FDA considers the 
direct advertising of clinical trials, not the presentation of an informed 
consent form and discussions guided by it, to be the start of the informed 
consent process.11 
We are making a logical extension of the FDA’s reasoning by 
suggesting that therapeutic misconception and misestimation can begin 
antecedent to a formal informed consent process. Therapeutic 
misconception refers to the documented difficulty people have in 
understanding the difference between clinical practice and investigation and 
what that difference means for their own care. Therapeutic misestimation 
refers to the documented tendency people have to inflate the potential 
benefits of clinical research.14 Given the prospect for antecedent therapeutic 
misconception and misestimation, it makes no difference whether the first 
impressions are the result of an advertisement about a specific trial or the 
result of a more general advertisement for the services and providers at the 
AMC where the trial is being conducted. Since AMC advertisements that 
promote “innovative” and “cutting edge” care are both sanctioned 
communications from the hospital and implicit endorsements of the clinical 
research they routinely conduct, they provide powerful and authoritative 
initial information about research. It is only reasonable, therefore, that 
consumers hold AMC advertisements in the same regard as the other 
9
institutionally sanctioned information that patients can draw upon in 
deciding about potential research participation.
Another objection is that AMC ads that tout research are meant to 
serve as patient education.15 When the American Hospital Association issued 
its first guidelines on appropriate advertising in 1977, two of the supported 
reasons for advertising were “public education about available services” and 
“public education about health care,”16 both of which remain a justification 
for hospital marketing today.17 “[P]roponents of hospital advertising 
emphasize issues of choice, access, and empowerment for their consumers, 
the potential patients.”18 Even when not pitched outright as education, 
marketing is sometimes presented as a service to patients that helps them 
better understand and discriminate among the range of services available.19 
The problem with this line of thought is twofold. First, one ought not 
assess the ethics of advertising just by looking at what an ad’s sponsor 
intends to convey. Given an AMC’s dual responsibilities to communicate 
accurately about research and to assure ethically valid informed consent, 
one must show equal regard for what ads can come to mean in the minds of 
research candidates, and thus how ads can later influence their 
decisionmaking. Second, advertisements by definition are meant to promote 
a product rather than educate. As such, they do not, and are not expected 
to, expound on risks, uncertainties, limitations, or alternatives to the 
treatment being touted.
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Some minimize the extent to which ads influence decisions by 
contending that use of words like “innovative” are not problematic because 
“advertising is simply not a superpowerful entity”20 controlling patient 
decisions. However, ample evidence shows that even important choices such
as those about health care and treatment can be influenced by very minor, 
nonrational factors that become part of what is known as the “frame effect” 
of decisionmaking. This refers to how people’s feelings about the source of 
information influence their evaluation of it.21 James Wright and his co-authors
explain that “beyond what patients read about the risks and benefits of a 
research protocol, other beliefs about the people requesting their 
participation will influence their decisions.”22 
In addition, many terms carry linguistic biases. Amos Tversky and 
Daniel Kahneman famously showed that decisions to undergo a medical 
procedure can be influenced by whether the risk is cast in terms of “survival”
or “mortality” rates.23 More recently, a study was conducted on the influence 
of “default options” on actual medical decisions. Seriously ill patients who 
were filling out advanced directives were sorted into three groups and 
assigned forms with different options set as the default choice. They were 
more likely to choose the default option regardless of what the default option
was.24 Another example of such nonrational influence comes from an 
experiment regarding health insurance plans on government exchange 
websites.25 On those websites, plans were grouped into categories of 
“bronze” (low premium, high out-of-pocket costs), “silver,” and “gold” (high 
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premium, low out-of-pocket costs). People tended to have a higher 
preference for “gold” plans. However, when the naming strategy was 
reversed (“bronze” having high premiums and low out-of-pocket costs and 
“gold” having low premiums and high out-of-pocket costs), people still 
preferred “gold” plans. 
Such evidence provides ample reason to think that ads can confuse 
patient perceptions of care by blurring clinical care and research. People 
exposed to AMC ads like ones the authors have firsthand knowledge of that 
claim, for example, that an AMC’s cancer center is someone’s “best hope for 
a cure” or that “your life is worth the trip” to a distant AMC, will struggle to 
understand the difference between standard care and experimentation, as 
well as the therapeutic prospects of research. They will find themselves in a 
clinical setting where they have been assured, through ads common to AMCs
that employ unrepresentative patient narratives or euphemistic terms like 
“innovation” and “pioneering” rather than the more forthright ones like 
“research” or “experimentation,” that this institution provides the best care 
available. All of this can corrode the informed consent process and thus 
diminish the careful deliberation about research participation that AMCs are 
responsible for encouraging in their research candidates. 
Second, even if one were to ethically assess ads simply on the 
information they convey, rather than their subsequent influence on 
decisionmaking, there is still an ethical obligation to provide balanced 
information about clinical research.26 This balance is lacking in the kinds of ad
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campaigns we are highlighting: heart-warming success stories fail to make 
clear, for example, that the treatments often described are experimental and
ads are also unalloyed by any talk of risks; they also fail to mention that only
about 15% of the drugs and devices studied in clinical trials eventually 
achieve regulatory approval, a figure that drops to 5% for the Phase I 
oncology trials at cancer centers.27 This last point is especially noteworthy in 
light of a recent study that showed that therapeutic misestimation occurred 
among 94% of participants in a Phase 1 trial.28 
Striking a Better Balance Between Marketing Needs and 
Responsible Communication
Despite our concerns about AMC marketing campaigns that highlight 
research, we want to be clear that we are not suggesting that all AMC 
advertisements are problematic. Our concerns are directed only at AMC 
advertisements that are directly at odds with the 2000 Reaffirmation of Trust
statement that stipulates that people should understand that research “may 
not benefit themselves in any way and may possibly harm them.” This 
pronouncement suggests that AMCs should look for ways to disrupt the 
impediments that therapeutic misestimation and misconception pose to 
ethically valid informed consent, yet if our analysis is correct, their marketing
strategies too often reinforce instead. 
No doubt this arises from there being no requirement that advertising 
campaigns undergo any type of prior ethics review like those required for 
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ads that recruit for individual clinical trials. Institutional Review Boards (IRB) 
must determine that such advertisements do not involve undue influence, 
that potential benefits stated in them are consistent with those spelled out in
informed consent forms, and that investigational drugs should not be 
advertised as a “new treatment” or “new medication.”29 Since there is no 
comparable oversight of marketing campaigns, AMCs will often lack the 
expertise that builds over time among IRB members that leaders could draw 
upon to help them recognize the extent to which marketing campaigns 
comport with an institution’s science communication and research ethics 
responsibilities. In such circumstances, a way forward is needed to remedy 
the situation.
What we think would be most beneficial in combating the excesses in 
marketing that highlights research is for AMC leaders, through their 
professional organizations, to grapple with how they can best strike a 
responsible balance between the critical monetary needs of their 
organizations and their equally critical obligations to communicate about and
conduct research ethically. Thus, we propose that the two major 
organizations that shepherd our nation’s AMCs, the AAMC and the 
Association of Academic Health Centers, convene a deliberative process that 
will develop a set of voluntary guidelines AMCs could rely upon to assure 
ethically responsible marketing campaigns that highlight, either directly or 
indirectly, their research missions. These two organizations could partner in 
this effort with others, such as research sponsors, clinical trialists, and 
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research participant advocates, to ensure representation and participation 
by important constituents in the process. 
This process could draw upon many resources: recently published 
guidelines by the International Society for Stem Cell Research that address 
responsible science communication,30 commentary by the Presidential 
Commission for the Study of Bioethical Issues that addresses hype in 
science,31 and the “Charter on Professionalism in Health Care” that 
emphasizes the promotion of health literacy and the commitment to ethical 
business practices.32 Numerous publications also make relevant 
recommendations about hospital marketing of clinical care.33-35  
Adequate guidelines should reflect the intrinsic ties between AMCs’ 
marketing messages about their research, and the future informed consent 
for research of individuals exposed to those messages. This includes 
following Lisa Schwartz and Steven Woloshin’s advice to distinguish between
appropriate and inappropriate uses of persuasive marketing approaches, and
to classify as “inappropriate” any ads with references to unproven or 
experimental procedures that blur their difference from quality care.36 
Further, the guidelines must account for the “typical patient’s combination of
vulnerability and inequity of knowledge,” and how this places the marketing 
of medical knowledge and services into a category distinct from that of other
consumer goods or services.37,38 
15
The guidelines should also stipulate internal review processes or other 
mechanisms that will help assure appropriate content in all advertising that 
highlights an institution’s research mission. This approach would signify that 
AMCs can place the fulfillment of ethical responsibilities intrinsic to their 
research mission on par with their commercial interests. It would also bring 
new substantive content and enumerated responsibilities to the AMCs who 
signed the 2000 Reaffirmation of Trust, and thereby strengthen their 
commitment to ethically communicate about and conduct research. Absent 
these basic features, the proposed guidelines will gain no traction against 
the interrelated problems caused by the ubiquitous hype and therapeutic 
misconception and misestimation that drive our concerns.
Though implementing new guidelines would no doubt represent new 
constraints on AMCs’ marketing efforts, we think constraints are needed, 
though they need not be as onerous as some may fear. The guidelines would
permit AMCs to employ marketing strategies that highlight the value of their 
research and celebrate their successes while also establishing needed 
safeguards. Recall that the point of AMC marketing campaigns is the 
protection and promotion of the multiple missions of AMCs. Irresponsible 
campaigns can undermine or jeopardize those missions because misleading 
and ethically irresponsible advertisements tarnish the reputation of AMCs by 
calling into question their commitment and ability to meet the high ethical 
standards of research they agreed to in the 2000 Reaffirmation of Trust. The 
guidelines we envision should help prevent irresponsible marketing and 
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thereby serve as a critical safeguard of the trust and goodwill that AMCs 
require, both from clinical research volunteers and the broader public, for 
their research missions in the first place. 
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